Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 446

1.

Open Access is the Plan S Way Forward in Hematology Research.

Cools J, Engert A, Gribben J, Macintyre E.

Hemasphere. 2020 Jan 15;4(1):e331. doi: 10.1097/HS9.0000000000000331. eCollection 2020 Feb. No abstract available.

2.

Real-time high-speed three-dimensional surface imaging using band-limited illumination profilometry with a CoaXPress interface.

Jiang C, Kilcullen P, Liu X, Gribben J, Boate A, Ozaki T, Liang J.

Opt Lett. 2020 Feb 15;45(4):964-967. doi: 10.1364/OL.378939.

PMID:
32058518
3.

A pilot study exploring interventions for physician distress in pediatric subspecialists.

Kase SM, Gribben JL, Waldman ED, Weintraub AS.

Pediatr Res. 2020 Feb 12. doi: 10.1038/s41390-020-0805-x. [Epub ahead of print]

PMID:
32054989
4.

Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?

Gribben JG.

Br J Haematol. 2020 Feb 9. doi: 10.1111/bjh.16470. [Epub ahead of print] No abstract available.

PMID:
32037510
5.

Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma.

Lazarian G, Friedrich C, Quinquenel A, Tran J, Ouriemmi S, Dondi E, Martin A, Mihoub I, Chiron D, Bellanger C, Fleury C, Gélébart P, McCormack E, Ledoux D, Thieblemont C, Marzec J, Gribben JG, Cymbalista F, Varin-Blank N, Gardano L, Baran-Marszak F.

Oncogene. 2020 Feb 7. doi: 10.1038/s41388-020-1183-x. [Epub ahead of print]

PMID:
32034308
6.

Here to Stay: Biosimilars in Hematology.

Gribben J, Merlini G, Hagenbeek A.

Hemasphere. 2019 Nov 19;3(6):e323. doi: 10.1097/HS9.0000000000000323. eCollection 2019 Dec. No abstract available.

7.

IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution.

Odabashian M, Carlotti E, Araf S, Okosun J, Spada F, Gribben JG, Forconi F, Stevenson F, Calaminici M, Krysov S.

Blood. 2020 Jan 13. pii: blood.2019002279. doi: 10.1182/blood.2019002279. [Epub ahead of print]

PMID:
31932843
8.

Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.

Gribben JG.

Br J Haematol. 2019 Dec 19. doi: 10.1111/bjh.16345. [Epub ahead of print] Review.

PMID:
31858596
9.

Dietary practices in methylmalonic acidaemia: a European survey.

Pinto A, Evans S, Daly A, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei SM, Bollhalder S, Cassiman D, Champion H, Chan H, Corthouts K, Dalmau J, Boer F, Laet C, Meyer A, Desloovere A, Dianin A, Dixon M, Dokoupil K, Dubois S, Eyskens F, Faria A, Fasan I, Favre E, Feillet F, Fekete A, Gallo G, Gingell C, Gribben J, Hansen KK, Horst NT, Jankowski C, Janssen-Regelink R, Jones I, Jouault C, Kahrs GE, Kok I, Kowalik A, Laguerre C, Verge SL, Liguori A, Lilje R, Maddalon C, Mayr D, Meyer U, Micciche A, Och U, Robert M, Rocha JC, Rogozinski H, Rohde C, Ross K, Saruggia I, Schlune A, Singleton K, Sjoqvist E, Skeath R, Stolen LH, Terry A, Timmer C, Tomlinson L, Tooke A, Kerckhove KV, van Dam E, Hurk DVD, Ploeg LV, van Driessche M, van Rijn M, Wegberg AV, Vasconcelos C, Vestergaard H, Vitoria I, Webster D, White F, White L, Zweers H, MacDonald A.

J Pediatr Endocrinol Metab. 2020 Jan 28;33(1):147-155. doi: 10.1515/jpem-2019-0277.

PMID:
31846426
10.

Phenotypic characterisation of regulatory T cells in dogs reveals signature transcripts conserved in humans and mice.

Wu Y, Chang YM, Stell AJ, Priestnall SL, Sharma E, Goulart MR, Gribben J, Xia D, Garden OA.

Sci Rep. 2019 Sep 17;9(1):13478. doi: 10.1038/s41598-019-50065-8.

11.

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.

J Clin Oncol. 2019 Dec 10;37(35):3359-3368. doi: 10.1200/JCO.19.00743. Epub 2019 Sep 9.

PMID:
31498031
12.

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1 regulated transcription.

Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, Dolnik A, Blätte TJ, Landau DA, Saub J, Estenfelder S, Ibach S, Cymbalista F, Leblond V, Delmer A, Bahlo J, Robrecht S, Fischer K, Goede V, Bullinger L, Wu CJ, Mertens D, Ficz G, Gribben JG, Hallek M, Döhner H, Stilgenbauer S.

Haematologica. 2019 Aug 29. pii: haematol.2019.217307. doi: 10.3324/haematol.2019.217307. [Epub ahead of print]

13.

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.

Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E, Spielewoy N, Fingerle-Rowson G, Harbron C, Mundt K, Wassner-Fritsch E, Cheson BD.

Leukemia. 2020 Feb;34(2):522-532. doi: 10.1038/s41375-019-0559-9. Epub 2019 Aug 28.

PMID:
31462735
14.

A randomized pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling during surgery.

Wodehouse T, Demopoulos M, Petty R, Miraki-Moud F, Belhaj A, Husband M, Fulton L, Randive N, Oksche A, Mehta V, Gribben J, Langford R.

Pain. 2019 Dec;160(12):2691-2698. doi: 10.1097/j.pain.0000000000001677.

PMID:
31433352
15.

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG.

Haematologica. 2019 Aug 14. pii: haematol.2019.223743. doi: 10.3324/haematol.2019.223743. [Epub ahead of print]

16.

Laparoscopic inguinal hernia repair in women: Trends, disparities, and postoperative outcomes.

Ilonzo N, Gribben J, Neifert S, Pettke E, Leitman IM.

Am J Surg. 2019 Oct;218(4):726-729. doi: 10.1016/j.amjsurg.2019.07.022. Epub 2019 Jul 22.

PMID:
31353033
17.

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.

Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D, Fegan C, McCaig A, Schuh A, Pettitt A, Gribben JG, Patten PEM, Devereux S, Bloor A, Fox CP, Forconi F, Munir T.

J Clin Oncol. 2019 Oct 20;37(30):2722-2729. doi: 10.1200/JCO.19.00894. Epub 2019 Jul 11.

PMID:
31295041
18.

Characteristics and Outcomes of Abdominal and Pelvic Trauma Patients With Psychiatric Illness.

Gribben JL, Ilonzo N, Neifert S, Hubert M, Leitman IM.

J Surg Res. 2019 Nov;243:440-446. doi: 10.1016/j.jss.2019.05.051. Epub 2019 Jul 4.

PMID:
31279984
19.

A Cross-sectional Analysis of Compassion Fatigue, Burnout, and Compassion Satisfaction in Pediatric Emergency Medicine Physicians in the United States.

Gribben JL, MacLean SA, Pour T, Waldman ED, Weintraub AS.

Acad Emerg Med. 2019 Jul;26(7):732-743. doi: 10.1111/acem.13670. Epub 2019 Jun 17.

PMID:
31204794
20.

Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study.

Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO; Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP).

BMC Gastroenterol. 2019 May 31;19(1):82. doi: 10.1186/s12876-019-0992-2.

21.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ.

Nature. 2019 Jun;570(7762):474-479. doi: 10.1038/s41586-019-1252-x. Epub 2019 May 29.

22.

Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.

Sun D, Stopka-Farooqui U, Barry S, Aksoy E, Parsonage G, Vossenkämper A, Capasso M, Wan X, Norris S, Marshall JL, Clear A, Gribben J, MacDonald TT, Buckley CD, Korbonits M, Haworth O.

Cell Rep. 2019 Apr 30;27(5):1461-1471.e4. doi: 10.1016/j.celrep.2019.04.014.

23.

Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma.

Zhang T, Guan XW, Gribben JG, Liu FT, Jia L.

Cell Death Dis. 2019 Apr 15;10(5):330. doi: 10.1038/s41419-019-1563-8.

24.

Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J, Clear A, Iqbal S, Davies JK, Johnson P, Calaminici M, Montoto S, Auer R, Chelala C, Gribben JG, Graham TA, Fest T, Fitzgibbon J, Okosun J.

Leukemia. 2019 Jun;33(6):1540. doi: 10.1038/s41375-019-0425-9.

PMID:
30903015
25.

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators.

J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21.

PMID:
30897038
26.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ.

Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.

27.

Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells.

Goulart MR, Hlavaty SI, Chang YM, Polton G, Stell A, Perry J, Wu Y, Sharma E, Broxholme J, Lee AC, Szladovits B, Turmaine M, Gribben J, Xia D, Garden OA.

Sci Rep. 2019 Mar 5;9(1):3574. doi: 10.1038/s41598-019-40285-3.

28.

Economic Disparities in Patients Undergoing Sigmoidectomy.

Neifert S, Ilonzo N, Gribben JL, Leitman IM.

JSLS. 2018 Oct-Dec;22(4). pii: e2018.00066. doi: 10.4293/JSLS.2018.00066.

29.

Development of national consensus statements on food labelling interpretation and protein allocation in a low phenylalanine diet for PKU.

British Inherited Metabolic Diseases Group (BIMDG) Dietitians Group, Evans S, Ford S, Adam S, Adams S, Ash J, Ashmore C, Caine G, Carruthers R, Cawtherley S, Chahal S, Clark A, Cochrane B, Daly A, Dines K, Dixon M, Dunlop C, Ellerton C, French M, Gaff L, Gingell C, Green D, Gribben J, Grimsley A, Hallam P, Hendroff U, Hill M, Hoban R, Howe S, Hunjan I, Kaalund K, Kelleher E, Khan F, Kitchen S, Lang K, Lowry S, Males J, Martin G, McStravick N, Micciche A, Newby C, Nicol C, Pereira R, Robertson L, Ross K, Simpson E, Singleton K, Skeath R, Stafford J, Terry A, Thom R, Tooke A, vanWyk K, White F, White L, MacDonald A.

Orphanet J Rare Dis. 2019 Jan 3;14(1):2. doi: 10.1186/s13023-018-0950-z.

30.
31.

Single cell analysis of clonal architecture in acute myeloid leukaemia.

Potter N, Miraki-Moud F, Ermini L, Titley I, Vijayaraghavan G, Papaemmanuil E, Campbell P, Gribben J, Taussig D, Greaves M.

Leukemia. 2019 May;33(5):1113-1123. doi: 10.1038/s41375-018-0319-2. Epub 2018 Dec 19.

32.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW.

Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30522969
33.

A Cross-Sectional Analysis of Compassion Fatigue, Burnout, and Compassion Satisfaction in Pediatric Critical Care Physicians in the United States.

Gribben JL, Kase SM, Waldman ED, Weintraub AS.

Pediatr Crit Care Med. 2019 Mar;20(3):213-222. doi: 10.1097/PCC.0000000000001803.

PMID:
30418339
34.

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol AM, Montoto S, Gribben JG, Calaminici M, Martinez A, Gonzalez-Farre B, Dlouhy I, González-Barca E, Terol MJ, Miralles P, Alcoceba M, Vall-Llovera F, Briones J, Abrisqueta P, Abella E, Provencio M, García-Ballesteros C, Moraleda JM, Sancho JM, Ribera JM, Mate JL, Navarro JT.

Leuk Lymphoma. 2019 Apr;60(4):1087-1091. doi: 10.1080/10428194.2018.1512711. Epub 2018 Oct 15. No abstract available.

PMID:
30322315
35.

Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.

Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P.

Am J Hematol. 2018 Nov;93(11):1402-1410. doi: 10.1002/ajh.25259. Epub 2018 Oct 9.

36.

No longer too exhausted to run.

Gribben JG.

Blood. 2018 Aug 2;132(5):464-465. doi: 10.1182/blood-2018-06-851642. No abstract available.

37.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

38.

How and when I do allogeneic transplant in CLL.

Gribben JG.

Blood. 2018 Jul 5;132(1):31-39. doi: 10.1182/blood-2018-01-785998. Epub 2018 May 11. Review.

40.

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.

Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S, Marfa S, Lea N, Best S, Gribben J, Fitzgibbon J, Cutillas PR.

Leukemia. 2018 Aug;32(8):1818-1822. doi: 10.1038/s41375-018-0032-1. Epub 2018 Apr 7. No abstract available.

41.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH.

J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.

PMID:
29584548
42.

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J, Clear A, Iqbal S, Davies JK, Johnson P, Calaminici M, Montoto S, Auer R, Chelala C, Gribben JG, Graham TA, Fest T, Fitzgibbon J, Okosun J.

Leukemia. 2018 May;32(5):1261-1265. doi: 10.1038/s41375-018-0043-y. Epub 2018 Feb 8. No abstract available. Erratum in: Leukemia. 2019 Jun;33(6):1540.

43.

Predictors of Reoperation and Failure to Rescue in Bariatric Surgery.

Gribben JL, Ilonzo N, Neifert S, Michael Leitman I.

JSLS. 2018 Jan-Mar;22(1). pii: e2017.00074. doi: 10.4293/JSLS.2017.00074.

44.

International practices in the dietary management of fructose 1-6 biphosphatase deficiency.

Pinto A, Alfadhel M, Akroyd R, Atik Altınok Y, Bernabei SM, Bernstein L, Bruni G, Caine G, Cameron E, Carruthers R, Cochrane B, Daly A, de Boer F, Delaunay S, Dianin A, Dixon M, Drogari E, Dubois S, Evans S, Gribben J, Gugelmo G, Heidenborg C, Hunjan I, Kok IL, Kumru B, Liguori A, Mayr D, Megdad E, Meyer U, Oliveira RB, Pal A, Pozzoli A, Pretese R, Rocha JC, Rosenbaum-Fabian S, Serrano-Nieto J, Sjoqvist E, Timmer C, White L, van den Hurk T, van Rijn M, Zweers H, Ziadlou M, MacDonald A.

Orphanet J Rare Dis. 2018 Jan 25;13(1):21. doi: 10.1186/s13023-018-0760-3.

45.

Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin.

Dürr C, Hanna BS, Schulz A, Lucas F, Zucknick M, Benner A, Clear A, Ohl S, Öztürk S, Zenz T, Stilgenbauer S, Li-Weber M, Krammer PH, Gribben JG, Lichter P, Seiffert M.

Haematologica. 2018 Apr;103(4):688-697. doi: 10.3324/haematol.2017.177808. Epub 2018 Jan 11.

46.

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.

Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, Moreno C, Stilgenbauer S.

Br J Haematol. 2018 Mar;180(5):666-679. doi: 10.1111/bjh.15080. Epub 2018 Jan 9. Review.

PMID:
29318593
47.

Acute myeloid leukemia xenograft success prediction: Saving time.

Griessinger E, Vargaftig J, Horswell S, Taussig DC, Gribben J, Bonnet D.

Exp Hematol. 2018 Mar;59:66-71.e4. doi: 10.1016/j.exphem.2017.12.002. Epub 2017 Dec 15.

48.

Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers.

Pearce OMT, Delaine-Smith RM, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D, Chakravarty P, Jones RR, Montfort A, Dowe T, Gribben J, Jones JL, Kocher HM, Serody JS, Vincent BG, Connelly J, Brenton JD, Chelala C, Cutillas PR, Lockley M, Bessant C, Knight MM, Balkwill FR.

Cancer Discov. 2018 Mar;8(3):304-319. doi: 10.1158/2159-8290.CD-17-0284. Epub 2017 Dec 1.

49.

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.

Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, Stewart A, Blackwood E, Bonnet D.

Nat Commun. 2017 Nov 22;8(1):1679. doi: 10.1038/s41467-017-01834-4.

50.

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors.

Saunderson EA, Stepper P, Gomm JJ, Hoa L, Morgan A, Allen MD, Jones JL, Gribben JG, Jurkowski TP, Ficz G.

Nat Commun. 2017 Nov 13;8(1):1450. doi: 10.1038/s41467-017-01078-2.

Supplemental Content

Loading ...
Support Center